Windward Bio raises USD 165M to advance new treatments for immune-related diseases

05.05.2026 09:37, Rita Longobardi

Windward Bio, a clinical-stage biotechnology company focused on immune-related diseases, has raised USD 165 million in new funding. The company has been building its drug pipeline quickly since its launch in early 2025 and is now advancing several treatments in clinical testing.

Windward Bio, ranked among the Top100 Swiss Startups last year, announced an upsized USD 165 million crossover financing round to support the development of its pipeline in immune-related diseases.

The company is focusing on conditions such as asthma and chronic lung disease. Its lead program, WIN378, is designed to reduce inflammation and is being developed as a long-acting treatment that could require dosing only a few times per year. It is currently being tested in mid-to-late stage clinical trials for asthma, with early results expected in 2026. Additional studies in chronic obstructive pulmonary disease (COPD) are also planned.

A second candidate, WIN027, targets two key inflammation pathways at once. It is in early clinical testing, with results expected by the end of 2026. If successful, it could be used across multiple diseases, including asthma and skin conditions.

The new funding will support ongoing clinical studies, help launch additional trials in 2026, and extend the company’s financial runway for its development programs.

Winward Bio's founder, Luca Santarelli